Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             55 results found
no title author magazine year volume issue page(s) type
1 Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Rizvi, Naiyer A
 2015
 16 3 p. 257-265
9 p.
 article
2 Adjuvant chemotherapy in locally advanced bladder cancer Lu, Kevin
 2015
 16 3 p. e103-e104
nvt p.
 article
3 Androgen deprivation with radiotherapy: how long is long enough? Gray, Phillip J
 2015
 16 3 p. 244-246
3 p.
 article
4 A stoic irreducibility: I Am Not The Cancer Pitt-Rashid, Josef James
 2015
 16 3 p. 255-256
2 p.
 article
5 Bevacizumab and quality of life in advanced cervical cancer Cella, David
 2015
 16 3 p. 241-243
3 p.
 article
6 Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology–Gynecologic Oncology Group protocol 240) Penson, Richard T
 2015
 16 3 p. 301-311
11 p.
 article
7 Body-mass index, cancer, and implications for screening Eveno, Clarisse
 2015
 16 3 p. e102-e103
nvt p.
 article
8 Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial Kunkler, Ian H
 2015
 16 3 p. 266-273
8 p.
 article
9 Canada removes ban on physician-assisted suicide Burki, Talha Khan
 2015
 16 3 p. e110-
1 p.
 article
10 Can older women with early breast cancer avoid radiation? Hughes, Kevin S
 2015
 16 3 p. 235-237
3 p.
 article
11 Correction to Lancet Oncol 2015; 16: 266 2015
 16 3 p. e105-
1 p.
 article
12 Correction to Lancet Oncol 2015; 16: 274 2015
 16 3 p. e105-
1 p.
 article
13 Correction to Lancet Oncol 2015; 16: 237 2015
 16 3 p. e105-
1 p.
 article
14 Correction to Lancet Oncol 2015; 16: 181, 184 2015
 16 3 p. e105-
1 p.
 article
15 Correction to Lancet Oncol 2015; 16: 133 2015
 16 3 p. e105-
1 p.
 article
16 Cruel imitation Ranscombe, Peter
 2015
 16 3 p. 253-254
2 p.
 article
17 Gene mutation order affects cancer behaviour Bagcchi, Sanjeet
 2015
 16 3 p. e112-
1 p.
 article
18 High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial Zapatero, Almudena
 2015
 16 3 p. 320-327
8 p.
 article
19 Hormone therapy increases ovarian cancer risk Tanday, Sanjay
 2015
 16 3 p. e112-
1 p.
 article
20 HPV vaccination unlikely to promote risky sexual behaviours Bagcchi, Sanjeet
 2015
 16 3 p. e111-
1 p.
 article
21 Hypofractionated radiotherapy in prostate cancer Dearnaley, David P
 2015
 16 3 p. 237-238
2 p.
 article
22 Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial Aluwini, Shafak
 2015
 16 3 p. 274-283
10 p.
 article
23 Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial Cesne, Axel Le
 2015
 16 3 p. 312-319
8 p.
 article
24 Japanese regulatory authority's perspective on biosimilars Nagai, Sumimasa
 2015
 16 3 p. e101-
1 p.
 article
25 Japanese regulatory authority's perspective on biosimilars – Authors' reply Bennett, Charles L
 2015
 16 3 p. e102-
1 p.
 article
26 Japanese universal health care faces a crisis in cancer treatment Fujiwara, Yasuhiro
 2015
 16 3 p. 251-252
2 p.
 article
27 Large degree of mutation in paediatric brain tumours Burki, Talha Khan
 2015
 16 3 p. e111-
1 p.
 article
28 Lenvatinib improves survival in refractory thyroid cancer Mayor, Susan
 2015
 16 3 p. e110-
1 p.
 article
29 Less surgery improves survival for advanced colorectal cancer Tanday, Sanjay
 2015
 16 3 p. e106-
1 p.
 article
30 Lifetime risk of cancer is more than 50% in Britain Tanday, Sanjay
 2015
 16 3 p. e109-
1 p.
 article
31 Minimally invasive test for Barrett's oesophagus Bagcchi, Sanjeet
 2015
 16 3 p. e109-
1 p.
 article
32 Morphogenetic fields of embryonic development in locoregional cancer spread Höckel, Michael
 2015
 16 3 p. e148-e151
nvt p.
 article
33 Moving the goal posts in prostate cancer trials Madan, Ravi A
 2015
 16 3 p. 247-249
3 p.
 article
34 Necitumumab for patients with non-squamous NSCLC: uninspiring results Zhou, Fei
 2015
 16 3 p. 246-247
2 p.
 article
35 Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study Paz-Ares, Luis
 2015
 16 3 p. 328-337
10 p.
 article
36 Nivolumab for advanced squamous cell lung cancer: what are the next steps? de Mello, Ramon Andrade
 2015
 16 3 p. 234-235
2 p.
 article
37 Nivolumab shows clinical activity in Hodgkin's lymphoma Bagcchi, Sanjeet
 2015
 16 3 p. e108-
1 p.
 article
38 Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014 Distelhorst, Sandra R
 2015
 16 3 p. e137-e147
nvt p.
 article
39 Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial Saad, Fred
 2015
 16 3 p. 338-348
11 p.
 article
40 PET-adapted salvage therapy in Hodgkin's lymphoma Tirelli, Umberto
 2015
 16 3 p. 239-240
2 p.
 article
41 PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study Moskowitz, Alison J
 2015
 16 3 p. 284-292
9 p.
 article
42 Prognostic accuracy in second-line renal cancer therapy Bex, Axel
 2015
 16 3 p. 240-241
2 p.
 article
43 Radiation therapy in the locoregional treatment of triple-negative breast cancer Moran, Meena S
 2015
 16 3 p. e113-e122
nvt p.
 article
44 Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group Armenian, Saro H
 2015
 16 3 p. e123-e136
nvt p.
 article
45 Rethinking trial eligibility in the NCD era The Lancet Oncology,
 2015
 16 3 p. 233-
1 p.
 article
46 Side-effects of cancer drugs are under-reported in trials Mayor, Susan
 2015
 16 3 p. e107-
1 p.
 article
47 Stereotactic radiosurgery alone for brain metastases Sahgal, Arjun
 2015
 16 3 p. 249-250
2 p.
 article
48 Targeted biopsy boosts detection of high-risk prostate cancer Tanday, Sanjay
 2015
 16 3 p. e107-
1 p.
 article
49 The art of living to the last Bagcchi, Sanjeet
 2015
 16 3 p. 256-
1 p.
 article
50 The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study Ko, Jenny J
 2015
 16 3 p. 293-300
8 p.
 article
51 The oncological package: a new source of concern in Poland's health system Holecki, Tomasz
 2015
 16 3 p. e104-
1 p.
 article
52 Trabectedin tactics: from sea squirts to sarcomas Randall, R Lor
 2015
 16 3 p. 243-244
2 p.
 article
53 UK and US governments to fund personalised medicine Burki, Talha
 2015
 16 3 p. e108-
1 p.
 article
54 Unmet needs of cancer survivors Burki, Talha Khan
 2015
 16 3 p. e106-
1 p.
 article
55 Wild: a journey through wilderness and memory Cagney, Hannah
 2015
 16 3 p. 254-255
2 p.
 article
                             55 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands